MARKET

SGMT

SGMT

Sagimet Biosciences Inc.
NASDAQ
9.67
-0.25
-2.47%
Opening 10:36 07/11 EDT
OPEN
9.76
PREV CLOSE
9.91
HIGH
9.91
LOW
9.34
VOLUME
332.70K
TURNOVER
--
52 WEEK HIGH
10.43
52 WEEK LOW
1.730
MARKET CAP
311.17M
P/E (TTM)
-5.4435
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 2d ago
Weekly Report: what happened at SGMT last week (0630-0704)?
Weekly Report · 4d ago
Weekly Report: what happened at SGMT last week (0623-0627)?
Weekly Report · 06/30 10:10
3 Best Stocks to Buy Now, 6/23/2025, According to Top Analysts
TipRanks · 06/23 12:12
Weekly Report: what happened at SGMT last week (0616-0620)?
Weekly Report · 06/23 10:07
TD Cowen Sticks to Its Buy Rating for Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 06/20 11:26
Buy Rating for Sagimet Biosciences Driven by Promising Clinical Data and Market Potential of Denifanstat
TipRanks · 06/19 06:07
Tracking Baker Brothers Portfolio - Q1 2025 Update
Seeking Alpha · 06/18 01:14
More
About SGMT
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Webull offers Sagimet Biosciences Inc stock information, including NASDAQ: SGMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMT stock methods without spending real money on the virtual paper trading platform.